It seems that the pharmaceutical industry’s increasing attention on patient centricity is starting to rub off on its corporate reputation, which has hit a four year-high according to findings of the latest PatientView survey.
Pharma’s standing in this respect has hit its highest level since 2011, when the PatientView survey began, with 44.7 percent of the 1,075 responding patient groups stating that it had an “Excellent” or “Good” corporate reputation in 2015, compared with just over a third in 2012, while 28 percent said its reputation had improved during the year.
The vast majority of patient groups responding (72 percent) said that pharma as a whole was “Excellent” or “Good” during the year at producing high-quality products. But, on the downside, just 15 percent said the industry was “Excellent” or “Good” at having fair pricing policies (and at not making excessive profits), while 45 percent said pharma was poor at this activity.
Overall, out of the 48 companies assessed for their corporate reputation by patient groups in 2015, ViiV Healthcare took the top spot again with AbbVie remaining a close second. Lundbeck moved up two places from 2014 to third place, Johnson & Johnson group Janssen jumped four place to fourth, Novo Nordisk slipped three place into fifth, and Gilead moved up eight places into 6th.
According to the report, a number of factors influence patient groups’ opinions on the corporate standing of pharma companies, including: product launches that offer a genuine, measurable and positive impact on a medical condition; mergers & acquisitions, which are not viewed favourable particularly if they target tax bills and overheads; and drug pricing and market access, one of the most sensitive topics for patient groups.
See the latest edition of PharmaTimes Magazine for more on patient centricity and pharma’s moves to boost reputation.
